Allos Pharma is a late-stage pharmaceutical company that is dedicated to improving the lives of patients with Fragile X Syndrome and Autism Spectrum Disorders. With a global team of experts in neuroscience and intellectual disabilities, Allos Pharma has been at the forefront of research in this field for over three decades. One of the key breakthroughs in their research is the mGluR theory of fragile X, proposed by MIT Professor Mark Bear and his collaborators in 2004.

This theory has paved the way for the development of disease-modifying therapies for Fragile X Syndrome and Autism Spectrum Disorder. Allos Pharma is committed to being the first to market an approved therapy for Fragile X Syndrome. Fragile X Syndrome is the most common single gene cause of intellectual disability and autism spectrum disorder.

It is associated with characteristic features such as intellectual disability, autism spectrum disorder, irritability, anxiety, and sensory hypersensitivity. Allos Pharma's mission is to develop therapies that address these symptoms and improve the quality of life for patients. Their main product, arbaclofen, is a potent and selective agonist of GABA-B receptors.

It effectively normalizes the excitatory:inhibitory balance in animal models of Fragile X Syndrome and Autism Spectrum Disorder. In clinical trials, arbaclofen has shown significant improvements in reducing irritable aberrant behavior in patients. Founded by renowned scientists Mark Bear and Randy Carpenter, Allos Pharma continues to lead the way in neurodevelopmental disorder research.

They have received guidance from the FDA for the design of a Phase 3 trial, demonstrating their commitment to bringing their therapies to market. Sign up for their newsletter to stay updated on their latest advancements in the field